{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:10:49Z","timestamp":1793211049489,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hemoglobin H (Hb H) disease is the most common form of thalassemia intermedia and has many features that require careful consideration in management. In the majority of cases, Hb H disease results from double heterozygosity for \u03b10-thalassemia due to deletions that remove both linked \u03b1-globin genes on chromosome 16, and deletional \u03b1+-thalassemia from single \u03b1-globin gene deletions (--\/\u2212\u03b1). However, Hb H disease may occur from interactions between \u03b10-thalassemia with non-deletional mutations (\u03b1T\u03b1 or \u03b1T) or with abnormal hemoglobins such as Hb Constant Spring, Hb Pakse\u0301, Hb Quong Sze, and Hb Pak Num Po. In a steady state, patients with Hb H diseases have hemoglobin levels around 9 to 10 g\/dL; however, during hemolytic crisis, which frequently develops in or after acute infections with high fever, the hemoglobin level may drop significantly and patients can develop shock or renal shutdown. Even though splenectomy leads to significant elevation of hemoglobin levels, it is not recommended because the majority of patients do well with said steady-state hemoglobin levels. Patients with non-deletional Hb H disease are usually more anemic with significant splenomegaly, and some may require regular blood transfusions and be even as severe as \u201cHb H hydrops fetalis.\u201d However, there is no clear genotype-phenotype correlation associated with this severe clinical syndrome since patients with identical genotypes do not necessary show the same severity. This suggests that other genetic and environmental factors play a role in modifying the degree of clinical severity in patients with non-deletional Hb H disease.<\/jats:p>","DOI":"10.1182\/asheducation-2009.1.26","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T20:35:31Z","timestamp":1260563731000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":155,"title":["Hb H disease: clinical course and disease modifiers"],"prefix":"10.1182","volume":"2009","author":[{"given":"Suthat","family":"Fucharoen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vip","family":"Viprakasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704200790400_R1","unstructured":"Higgs DR. Molecular mechanism of \u03b1 thalassemia. In: Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of Hemoglobin. Cambridge University Press; 2001:405\u2013430."},{"key":"2019111704200790400_R2","doi-asserted-by":"crossref","unstructured":"Viprakasit V, Harteveld CL, Ayyub H, Stanley JS, Giodano PC, Higgs DR. A novel deletion causing \u03b1 thalassemia clarifies the importance of the major human alpha globin regulatory element. Blood. 2006:107:3811\u20133812.","DOI":"10.1182\/blood-2005-12-4834"},{"key":"2019111704200790400_R3","unstructured":"Wasi P, Na-Nakorn S, Pootrakul S-N. The \u03b1 thalassemias. Clin Haematol. 1974;3:383\u2013410."},{"key":"2019111704200790400_R4","unstructured":"Fucharoen S, Winichagoon P, Pootrakul P, Piankijagum A, Wasi P. Differences between two types of Hb H disease, \u03b1-thalassemia 1\/\u03b1-thalassemia 2 and \u03b1-thalassemia 1\/Hb Constant Spring. Birth Defects Orig Artic Ser. 1988;23:309\u2013315."},{"key":"2019111704200790400_R5","doi-asserted-by":"crossref","unstructured":"Chan V, Chan TK, Todd D. Different forms of Hb H disease in the Chinese. Hemoglobin. 1988;12:499\u2013507.","DOI":"10.3109\/03630268808991638"},{"key":"2019111704200790400_R6","doi-asserted-by":"crossref","unstructured":"Galanello R, Aru B, Dess C, et al. Hb H disease in Sardinia: molecular, hematological and clinical aspects. Acta Haematol. 1992;88:1\u20136.","DOI":"10.1159\/000204585"},{"key":"2019111704200790400_R7","unstructured":"Ma ESK, Chow EYD, Chan AYY, Chan LC. Interaction between (--SEA) \u03b1-thalassemia deletion and uncommon non-deletional \u03b1-globin gene mutations in Chinese patients. Hematologica. 2001;86:539\u2013540."},{"key":"2019111704200790400_R8","unstructured":"Viprakasit V, Tanphaichitr VS, Pung-Amritt P, et al. Clinical phenotypes and molecular characterization of Hb H-Pakse disease. Hematologica. 2002;87:117\u2013125."},{"key":"2019111704200790400_R9","doi-asserted-by":"crossref","unstructured":"Viprakasit V, Green S, Height S, Ayyub H, Higgs DR. Hb H hydrops fetalis syndrome associated with the interaction of two common determinants of \u03b1 thalassemia ( --MED\/\u03b1TSaudi \u03b1 ). Br J Haematol. 2002;117:759\u2013762.","DOI":"10.1046\/j.1365-2141.2002.03427.x"},{"key":"2019111704200790400_R10","doi-asserted-by":"crossref","unstructured":"Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood. 2003;101:791\u2013800.","DOI":"10.1182\/blood-2002-07-1975"},{"key":"2019111704200790400_R11","unstructured":"Chandrcharoensin-Wilde C, Chairoongruang S, Jitnuson P, Fucharoen S, Vathanopas V. Gallstones in thalassemia. Birth Defects Orig Artic Ser. 1988;23:263\u2013267."},{"key":"2019111704200790400_R12","doi-asserted-by":"crossref","unstructured":"Viprakasit V, Tanphaichitr VS, Veerakul G, et al. Co-inheritance of Hb Pak Num Po, a novel alpha1 gene mutation, and alpha0 thalassemia associated with transfusion-dependent Hb H disease. Am J Hematol. 2004;75:157\u2013163.","DOI":"10.1002\/ajh.10479"},{"key":"2019111704200790400_R13","doi-asserted-by":"crossref","unstructured":"Henderson S, Pitman M, McCarthy J, Molyneux A, Old J. Molecular prenatal diagnosis of Hb H hydrops fetalis caused by haemoglobin Adana and the implications to antenatal screening for alpha-thalassaemia. Prenat Diagn. 2008;28:859\u2013861.","DOI":"10.1002\/pd.2045"},{"key":"2019111704200790400_R14","doi-asserted-by":"crossref","unstructured":"Li DZ, Liao C, Li J, Xie XM, Huang YN, Wu QC. Hemoglobin H hydrops fetalis syndrome resulting from the association of the --SEA deletion and the alphaQuong Sze alpha mutation in a Chinese woman. Eur J Haematol. 2005;75:259\u2013261.","DOI":"10.1111\/j.1600-0609.2005.00493.x"},{"key":"2019111704200790400_R15","doi-asserted-by":"crossref","unstructured":"Charoenkwan P, Sirichotiyakul S, Chanprapaph P, et al. Anemia and hydrops in a fetus with homozygous hemoglobin constant spring. J Pediatr Hematol Oncol. 2006;28:827\u2013830.","DOI":"10.1097\/01.mph.0000243662.56432.37"},{"key":"2019111704200790400_R16","unstructured":"Fucharoen S, Winichagoon P, Piankijagum A. Standardization on laboratory diagnosis of thalassemia and abnormal hemoglobin. Southeast Asian J Trop Med Public Health. 1999;30 Suppl 3:90\u201398."},{"key":"2019111704200790400_R17","doi-asserted-by":"crossref","unstructured":"Winichagoon P, Svasti S, Munkongdee T, et al. Rapid diagnosis of thalassemias and other hemoglobinopathies by capillary electrophoresis system. Transl Res. 2008;152:178\u2013184.","DOI":"10.1016\/j.trsl.2008.08.004"},{"key":"2019111704200790400_R18","doi-asserted-by":"crossref","unstructured":"Chui DH. Alpha-thalassemia: Hb H disease and Hb Barts hydrops fetalis. Ann N Y Acad Sci. 2005;1054:25\u201332.","DOI":"10.1196\/annals.1345.004"},{"key":"2019111704200790400_R19","doi-asserted-by":"crossref","unstructured":"Jetsrisuparb A, Sanchaisuriya K, Fucharoen G, et al. Development of severe anemia during fever episodes in patients with hemoglobin E trait and hemoglobin H disease combinations. J Pediatr Hematol Oncol. 2006;28:249\u2013253.","DOI":"10.1097\/01.mph.0000212910.99394.e0"},{"key":"2019111704200790400_R20","unstructured":"Slomp J, Bosschaart A, Dousma M, van Zwieten R, Giordano PC, van den Bergh FA. [Acute anaemia in a Vietnamese patient with alpha-thalassaemia and a parvovirus infection]. Ned Tijdschr Geneeskd. 2006;150:1577\u20131582."},{"key":"2019111704200790400_R21","doi-asserted-by":"crossref","unstructured":"Yaegashi N, Niinuma T, Chisaka H, et al. Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo. J Infect. 1999;39:68\u201376.","DOI":"10.1016\/S0163-4453(99)90105-6"},{"key":"2019111704200790400_R22","doi-asserted-by":"crossref","unstructured":"Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15:485\u2013505.","DOI":"10.1128\/CMR.15.3.485-505.2002"},{"key":"2019111704200790400_R23","unstructured":"Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007;75:373\u2013376."},{"key":"2019111704200790400_R24","unstructured":"Al-Salem AH, Nasserulla Z. Splenectomy for children with thalassemia. Int Surg. 2002;87:269\u2013273."},{"key":"2019111704200790400_R25","doi-asserted-by":"crossref","unstructured":"Viprakasit V, Vathesathokit P, Chinchang W, et al. Prevalence of HFE mutations among the Thai population and correlation with iron loading in haemoglobin E disorder. Eur J Haematol. 2004;73:43\u201349.","DOI":"10.1111\/j.1600-0609.2004.00246.x"},{"key":"2019111704200790400_R26","doi-asserted-by":"crossref","unstructured":"Martins R, Picanco I, Fonseca A, et al. The role of HFE mutations on iron metabolism in beta-thalassemia carriers. J Hum Genet. 2004;49:651\u2013655.","DOI":"10.1007\/s10038-004-0202-z"},{"key":"2019111704200790400_R27","doi-asserted-by":"crossref","unstructured":"Chen FE, Ooi C, Ha SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med. 2000;343:544\u2013550.","DOI":"10.1056\/NEJM200008243430804"},{"key":"2019111704200790400_R28","doi-asserted-by":"crossref","unstructured":"Tankanitlert J, Morales NP, Fucharoen P, Fucharoen S, Chantharaksri U. Association between promoter and coding region mutations of UDP-glucuronosyltransferase 1A1 and beta-thalassemia\/Hb E with cholelithiasis. Eur J Haematol. 2008;80:351\u2013355.","DOI":"10.1111\/j.1600-0609.2007.01010.x"},{"key":"2019111704200790400_R29","unstructured":"Koiso H, Kin Y, Narahara N, et al. [alpha-thalassemia accompanied with Gilbert\u2019s syndrome]. Rinsho Ketsueki. 1998;39:703\u2013708."},{"key":"2019111704200790400_R30","doi-asserted-by":"crossref","unstructured":"Au WY, Cheung WC, Hu WH, et al. Hyperbilirubinemia and cholelithiasis in Chinese patients with hemoglobin H disease. Ann Hematol. 2005;84:671\u2013674.","DOI":"10.1007\/s00277-005-1091-8"},{"key":"2019111704200790400_R31","unstructured":"Traeger-Synodinos J, Papassotiriou I, Vrettou C, Skarmoutsou C, Stamoulakatou A, Kanavakis E. Erythroid marrow activity and functional anemia in patients with the rare interaction of a single functional \u03b1-globin and beta-globin gene. Haematologica. 2001;86:363\u2013367."},{"key":"2019111704200790400_R32","unstructured":"Ma ES, Chan AY, Au WY, Yeung YM, Chan LC. Diagnosis of concurrent hemoglobin H disease and heterozygous beta-thalassemia. Haematologica. 2001;86:432\u2013433."},{"key":"2019111704200790400_R33","doi-asserted-by":"crossref","unstructured":"Thonglairuam V, Winichagoon P, Fucharoen S, Wasi P. The molecular basis of AE-Bart\u2019s disease. Hemoglobin. 1989;13:117\u2013124.","DOI":"10.3109\/03630268908998061"},{"key":"2019111704200790400_R34","doi-asserted-by":"crossref","unstructured":"Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell. 1995;80:837\u2013845.","DOI":"10.1016\/0092-8674(95)90287-2"},{"key":"2019111704200790400_R35","doi-asserted-by":"crossref","unstructured":"Gibbons RJ, Higgs DR. Molecular-clinical spectrum of the ATR-X syndrome. Am J Med Genet. 2000;97:204\u2013212.","DOI":"10.1002\/1096-8628(200023)97:3<204::AID-AJMG1038>3.0.CO;2-X"},{"key":"2019111704200790400_R36","doi-asserted-by":"crossref","unstructured":"Higgs DR, Garrick D, Anguita E, et al. Understanding alpha-globin gene regulation: Aiming to improve the management of thalassemia. Ann N Y Acad Sci. 2005;1054:92\u2013102.","DOI":"10.1196\/annals.1345.012"},{"key":"2019111704200790400_R37","doi-asserted-by":"crossref","unstructured":"Vasseur-Godbillon C, Marden MC, Giordano P, Wajcman H, Baudin-Creuza V. Impaired binding of AHSP to alpha chain variants: Hb Groene Hart illustrates a mechanism leading to unstable hemoglobins with alpha thalassemic like syndrome. Blood Cells Mol Dis. 2006;37:173\u2013179.","DOI":"10.1016\/j.bcmd.2006.09.002"},{"key":"2019111704200790400_R38","doi-asserted-by":"crossref","unstructured":"Zhou S, Olson JS, Fabian M, Weiss MJ, Gow AJ. Biochemical fates of alpha hemoglobin bound to alpha hemoglobin-stabilizing protein AHSP. J Biol Chem. 2006;281:32611\u201332618.","DOI":"10.1074\/jbc.M607311200"},{"key":"2019111704200790400_R39","doi-asserted-by":"crossref","unstructured":"Chinprasertsuk S, Wanachiwanawin W, Piankijagum A. Effect of pyrexia in the formation of intraerythrocytic inclusion bodies and vacuoles in haemolytic crisis of haemoglobin H disease. Eur J Haematol. 1994;52:87\u201391.","DOI":"10.1111\/j.1600-0609.1994.tb01291.x"},{"key":"2019111704200790400_R40","doi-asserted-by":"crossref","unstructured":"Beigi RH, Wiesenfeld HC, Landers DV, Simhan HN. High rate of severe fetal outcomes associated with maternal parvovirus b19 infection in pregnancy. Infect Dis Obstet Gynecol. 2008;2008:524601.","DOI":"10.1155\/2008\/524601"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/26\/645585\/026_034ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2009\/1\/26\/645585\/026_034ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:20:26Z","timestamp":1573982426000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2009\/1\/26\/19886\/Hb-H-disease-clinical-course-and-disease-modifiers"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2009.1.26","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,1]]}}}